Get the Stockscreener App
96.86
0.74%
-0.72
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $96.86, with a volume of 7.19M.
It is down -0.74% in the last 24 hours and down -1.76% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$97.58
Open:
$97.18
24h Volume:
7.19M
Relative Volume:
0.92
Market Cap:
$124.18B
Revenue:
$35.48B
Net Income/Loss:
$4.64B
P/E Ratio:
27.01
EPS:
3.5856
Net Cash Flow:
$5.41B
1W Performance:
-2.64%
1M Performance:
-1.76%
6M Performance:
+3.90%
1Y Performance:
+10.14%
1-Day Range:
$96.47
$97.86
1-Week Range:
$95.50
$98.72
52-Week Range:
$79.55
$106.33
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT vs ABT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Resumed | Barclays | Overweight |
| Feb-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-03-26 | Resumed | Citigroup | Buy |
| Jan-30-26 | Resumed | Wells Fargo | Overweight |
| Jan-06-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-19-25 | Upgrade | Goldman | Sell → Neutral |
| Jun-30-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
| Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-24 | Reiterated | Oppenheimer | Perform |
| Aug-15-24 | Upgrade | UBS | Sell → Neutral |
| Aug-14-24 | Downgrade | Stifel | Buy → Hold |
| May-30-24 | Initiated | Goldman | Sell |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-29-23 | Downgrade | UBS | Buy → Sell |
| Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-10-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-08-20 | Upgrade | Stifel | Hold → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| May-14-20 | Downgrade | DZ Bank | Buy → Hold |
| Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
| Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Sell |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Feb-04-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Medtronic (NYSE:MDT) Rating Increased to Buy at Wall Street Zen - MarketBeat
Important takeaways from Medtronic’s (MDT) Q3 2026 earnings report - AlphaStreet News
Pharaoh Neuro raises $20m, picks ex-Medtronic exec for CEO role - Medical Device Network
Medtronic’s blood pressure device wins coverage nod in Japan - MedTech Dive
Medtronic to cut 81 employees at California diabetes site - MedTech Dive
Medtronic PLC $MDT Shares Sold by Pekin Hardy Strauss Inc. - MarketBeat
Medtronic (NYSE:MDT) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
How Medtronic (NYSE:MDT) Reacts To Market Sentiment In S&P 500 Futures - Kalkine Media
Medtronic’s hypertension treatment receives reimbursement approval in Japan By Investing.com - Investing.com Nigeria
Tele-Monitoring Services: Growing at 18% CAGR, Bringing Health Closer to Families - GlobeNewswire Inc.
Medtronic : Receives Reimbursement Approval for Symplicity Spyral™ Renal Denervation System in Japan - marketscreener.com
Comgest Global Investors S.A.S. Sells 13,291 Shares of Medtronic PLC $MDT - MarketBeat
Pzena Investment Management LLC Reduces Holdings in Medtronic PLC $MDT - MarketBeat
Medtronic Exec Alleges Retaliatory Firing For Whistleblowing - Law360
Truist Securities Cuts Price Target on Medtronic to $103 From $107, Maintains Hold Rating - marketscreener.com
Medtronic PLC (NYSE:MDT) Margin Contracts - FXDailyReport.Com
Medtronic nets FDA clearance for robotic spine system - MedTech Dive
Medtronic Analysts Cut Their Forecasts After Q3 Earnings - Benzinga
Medtronic plc (NYSE:MDT) Q3 2026 Earnings Call Transcript - Insider Monkey
Leerink Partners Adjusts Price Target on Medtronic to $119 From $120, Maintains Outperform Rating - marketscreener.com
Needham & Company LLC Cuts Medtronic (NYSE:MDT) Price Target to $120.00 - MarketBeat
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Cadence Design, Crox, Genuine Parts, Kratos Defense, Medtronic, Palantir, StubHub, Transocean, and More - 24/7 Wall St.
Medtronic’s Q3 2026 revenues reach $9bn on strong PFA demand - Yahoo Finance
Barclays Adjusts Price Target on Medtronic to $118 From $116, Maintains Overweight Rating - marketscreener.com
JPMorgan Adjusts Price Target on Medtronic to $100 From $105, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on Medtronic to $100 From $103, Maintains Neutral Rating - marketscreener.com
Advisors Capital Management LLC Grows Stake in Medtronic PLC $MDT - MarketBeat
Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case For Medtronic (MDT)? - Yahoo Finance
Medtronic plc Q3 FY2026 Earnings: Revenue Hits $9.0B With Highest Enterprise Growth in 10 Quarters - Bayelsa Watch
NEOS Investment Management LLC Grows Position in Medtronic PLC $MDT - MarketBeat
Medtronic completes first Hugo case in the US - MedTech Dive
Medtronic (NYSE:MDT) Balance Sheet Discipline Underscored In S&P 500 Index - Kalkine Media
Medtronic earns FDA clearance for Stealth AXiS spinal surgery system - The Robot Report
Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026? - Yahoo Finance
Medtronic Just Posted Its Best Quarter in 2.5 Years - AOL.com
Medtronic Announces FDA approval of Infuse™ bone graft for one-and-two level Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures - Ortho Spine News
Medtronic PLC (MDT) Q3 2026 Earnings Call Highlights: Strong Cardiovascular Growth and ... By GuruFocus - Investing.com Canada
Medtronic completes first U.S. cases with Hugo - MassDevice
Gold down 3%; Medtronic earnings top views - MSN
Medtronic gets FDA nod for Infuse bone graft in TLIF procedures - MassDevice
Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth - Benzinga
Medtronic Q3 Earnings Call Highlights - MarketBeat
Medtronic plc Q3 2026 Earnings Call Summary - Yahoo Finance
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down - The Globe and Mail
Medtronic Q3 FY26 slides reveal strongest revenue growth in 10 quarters, stock dips - Investing.com
Medtronic : Announces FDA approval of Infuse™ bone graft for one-and-two level Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures - marketscreener.com
Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic - BioSpace
Medtronic stock falls despite Q3 beat, Gemini's C-Suite shakeup - Yahoo Finance
Medtronic tops Q3 forecasts with strongest revenue growth in 10 quarters - MSN
Medtronic plc (MDT) Stock: Surge in Cardiac Ablation and Diabetes Revenue Fuels Strong Q3 - CoinCentral
Medtronic slides as unchanged outlook meets consensus amid tariff impact - MSN
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):